(Q37875792)

24 August 2017

1 reference

title

Antiangiogenic treatments and mechanisms of action in renal cell carcinoma (English)

1 reference

24 August 2017

main subject

angiogenesis inhibitor

1 reference

Sylvie Négrier

1

1 reference

24 August 2017

Eric Raymond

series ordinal

2

1 reference

24 August 2017

publication date

15 May 2011

1 reference

Investigational New Drugs

24 August 2017

published in

1 reference

24 August 2017

volume

30

1 reference

24 August 2017

issue

4

1 reference

24 August 2017

page(s)

1791-1801

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-011-9677-6

24 August 2017

exact match

0 references

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Biology of gastrointestinal stromal tumors: KIT mutations and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Signal transduction and oncogenesis by ErbB/HER receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

VEGF-targeted therapy: mechanisms of anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Complexity of tumor vasculature in clear cell renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Platelet-derived growth factor-B enhances glioma angiogenesis by stimulating vascular endothelial growth factor expression in tumor endothelia and by promoting pericyte recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

PDGF receptors as cancer drug targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Blocking platelet-derived growth factor-D/platelet-derived growth factor receptor beta signaling inhibits human renal cell carcinoma progression in an orthotopic mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Rhebbing up mTOR: New Insights on TSC1 and TSC2, and the Pathogenesis of Tuberous Sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Raf: a strategic target for therapeutic development against cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

An orally administered multitarget tyrosine kinase inhibitor, SU11248, is a novel potent inhibitor of thyroid oncogenic RET/papillary thyroid cancer kinases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Phase I trial of pazopanib in patients with advanced cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

AZD2171 shows potent antitumor activity against gastric cancer over-expressing fibroblast growth factor receptor 2/keratinocyte growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Plethora of agents, plethora of targets, plethora of side effects in metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Sorafenib in advanced clear-cell renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

A quantitative analysis of kinase inhibitor selectivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Metastatic renal cell cancer treatments: an indirect comparison meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Treatment selection for patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Different vascular endothelial growth factor (VEGF), VEGF-receptor 1 and -2 mRNA expression profiles between clear cell and papillary renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Mechanisms of adverse effects of anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Subungual splinter hemorrhages: a clinical window to inhibition of vascular endothelial growth factor receptors?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Angiogenesis in the thyroid gland

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Upregulation of the angiogenic factors PlGF, VEGF and their receptors (Flt-1, Flk-1/KDR) by TSH in cultured thyrocytes and in the thyroid gland of thiouracil-fed rats suggest a TSH-dependent paracrine mechanism for goiter hypervascularization

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Presence and possible role of vascular endothelial growth factor in thyroid cell growth and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Phase I clinical study of AZD2171, an oral vascular endothelial growth factor signaling inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

BAY 43-9006 inhibition of oncogenic RET mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Hypoxia-inducible factor 1-alpha reduces infarction and attenuates progression of cardiac dysfunction after myocardial infarction in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Modulation of growth factor action: implications for the treatment of cardiovascular diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Sorafenib reveals efficacy in sequential treatment of metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Combination targeted therapy in advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Different isoform patterns for vascular endothelial growth factor between clear cell and papillary renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Hypoxia inducible factor-1 expression mediates myocardial response to ischemia late after acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-011-9677-6

Tivozanib, a pan-VEGFR tyrosine kinase inhibitor for the potential treatment of solid tumors.

21 January 2018

1 reference

12 December 2020

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

12 December 2020

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer

1 reference

12 December 2020

Targeted therapy for metastatic renal cell carcinoma

1 reference

12 December 2020

Increased serum vascular endothelial growth factor levels and intrathyroidal vascular area in patients with Graves' disease and Hashimoto's thyroiditis

1 reference

12 December 2020

The role of mammalian target of rapamycin inhibitors in the treatment of advanced renal cancer

1 reference

12 December 2020

Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition

1 reference

12 December 2020

Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies.

1 reference

12 December 2020

Expression of platelet-derived growth factor-alpha alpha receptor is associated with tumor progression in clear cell renal cell carcinoma

1 reference

12 December 2020

Severe skin reaction in a patient with gastrointestinal stromal tumor treated with imatinib mesylate

1 reference

12 December 2020

Hypothyroidism in patients with renal cell carcinoma: blessing or curse?

1 reference

12 December 2020

Intragenic PTEN/MMAC1 loss of heterozygosity in conventional (clear-cell) renal cell carcinoma is associated with poor patient prognosis

1 reference

12 December 2020

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

1 reference

12 December 2020

Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis

1 reference

12 December 2020

The tyrosine kinase inhibitor, AZD2171, inhibits vascular endothelial growth factor receptor signaling and growth of anaplastic thyroid cancer in an orthotopic nude mouse model

1 reference

12 December 2020

10.1007/S10637-011-9677-6

Identifiers

DOI

1 reference

24 August 2017

1 reference